Foscarnet — Membership Pricing

Other medications in Infections

• Fosfomycin
• Ganciclovir
• Imipenem-Cilastatin
• Isoniazid
• Itraconazole
• Ketoconazole
• Lamivudine
• Ledipasvir

About Foscarnet

Foscarnet is a crucial antiviral medication used to treat serious viral infections, particularly in immunocompromised individuals. Given its specialized nature and administration, understanding its role and cost can be vital. At TheDrugClub, we aim to make essential medications like foscarnet more accessible by helping our members navigate pricing and potential savings.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Foscarnet is approved for (FDA label)

CMV Retinitis Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium injection and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections Foscarnet sodium injection is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS.

Source: Read the full FDA label on DailyMed. Label effective date: June 25, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Foscarnet (FDA label)

WARNING RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF FOSCARNET SODIUM INJECTION. FREQUENT MONITORING OF SERUM CREATININE, WITH DOSE ADJUSTMENT FOR CHANGES IN RENAL FUNCTION, AND ADEQUATE HYDRATION WITH ADMINISTRATION OF FOSCARNET SODIUM INJECTION IS IMPERATIVE (see ADMINISTRATION section ; Hydration). SEIZURES, RELATED TO ALTERATIONS IN PLASMA MINERALS AND ELECTROLYTES, HAVE BEEN ASSOCIATED WITH FOSCARNET SODIUM INJECTION TREATMENT. THEREFORE, PATIENTS MUST BE CAREFULLY MONITORED FOR SUCH CHANGES AND THEIR POTENTIAL SEQUELAE. MINERAL AND ELECTROLYTE SUPPLEMENTATION MAY BE REQUIRED. FOSCARNET SODIUM INJECTION IS INDICATED FOR USE ONLY IN IMMUNOCOMPROMISED PATIENTS WITH CMV RETINITIS AND MUCOCUTANEOUS ACYCLOVIR-RESISTANT HSV INFECTIONS (see INDICATIONS section ).

Source: FDA prescribing information (DailyMed). Set ID: b03cbb8e-f555-4ed3-854e-dd962604f144. SPL document ID: 9f368bb0-0e5d-47f4-9d56-a838da0a7eba. Label effective date: June 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Foscarnet (FDA label)

THE MAJOR TOXICITY OF FOSCARNET SODIUM IS RENAL IMPAIRMENT (see WARNINGS section ). Approximately 33% of 189 patients with AIDS and CMV retinitis who received foscarnet sodium (60 mg/kg TID), without adequate hydration, developed significant impairment of renal function (serum creatinine ≥ 2.0 mg/dL). The incidence of renal impairment in subsequent clinical trials in which 1,000 mL of normal saline or 5% dextrose solution was given with each infusion of foscarnet sodium was 12% (34/280). Foscarnet sodium has been associated with changes in serum electrolytes including hypocalcemia (15% to 30%), hypophosphatemia (8% to 26%) and hyperphosphatemia (6%), hypomagnesemia (15% to 30%), and hypokalemia (16% to 48%) (see WARNINGS section ). The higher percentages were derived from those patients receiving hydration.

Source: FDA prescribing information (DailyMed). Set ID: b03cbb8e-f555-4ed3-854e-dd962604f144. SPL document ID: 9f368bb0-0e5d-47f4-9d56-a838da0a7eba. Label effective date: June 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Foscarnet (FDA label)

Foscarnet sodium injection is contraindicated in patients with clinically significant hypersensitivity to foscarnet sodium.

Source: FDA prescribing information (DailyMed). Set ID: b03cbb8e-f555-4ed3-854e-dd962604f144. SPL document ID: 9f368bb0-0e5d-47f4-9d56-a838da0a7eba. Label effective date: June 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Foscarnet (FDA label)

A possible drug interaction of foscarnet sodium and intravenous pentamidine has been described. Concomitant treatment of four patients in the United Kingdom with foscarnet sodium and intravenous pentamidine may have caused hypocalcemia; one patient died with severe hypocalcemia. Toxicity associated with concomitant use of aerosolized pentamidine has not been reported. Because foscarnet sodium can reduce serum levels of ionized calcium, extreme caution is advised when used concurrently with other drugs known to influence serum calcium levels (e.g., intravenous pentamidine). Renal impairment and symptomatic hypocalcemia have been observed during concurrent treatment with foscarnet sodium and intravenous pentamidine. Because of foscarnet’s tendency to cause renal impairment, the use of foscarnet sodium should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient.

Source: FDA prescribing information (DailyMed). Set ID: b03cbb8e-f555-4ed3-854e-dd962604f144. SPL document ID: 9f368bb0-0e5d-47f4-9d56-a838da0a7eba. Label effective date: June 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.